
1. virus genes. 2017 aug;53(4):501-515. doi: 10.1007/s11262-017-1455-x. epub 2017
apr 26.

ebola marburg virus vaccines.

reynolds p(1), marzi a(2).

author information: 
(1)laboratory virology, division intramural research, national institute of
allergy infectious diseases, national institutes health, hamilton, mt,
usa.
(2)laboratory virology, division intramural research, national institute of
allergy infectious diseases, national institutes health, hamilton, mt,
usa. marzia@niaid.nih.gov.

the filoviruses, ebola virus (ebov), marburg virus (marv), among most
pathogenic viruses known man causative agents viral hemorrhagic
fever outbreaks africa case fatality rates 90%. nearly 30,000
infections observed latest ebov epidemic west africa; previous
outbreaks much smaller, typically affecting less hundred
people. compared diseases aids malaria millions cases
annually, filovirus hemorrhagic fever (fhf) one neglected infectious
diseases. licensed vaccines therapeutics available treat ebov 
and marv infections; therefore, pathogens handled maximum
containment laboratories classified select agents. these
limitations, laboratories worldwide conducted basic research and
countermeasure development ebov marv since respective discoveries
in 1967 (marv) 1976 (ebov). review, discuss several vaccine
platforms ebov marv, assessed protective
efficacy animal models fhf. focus promising approaches, 
which accelerated clinical development (phase i-iii trials) the
ebov epidemic west africa.

doi: 10.1007/s11262-017-1455-x 
pmcid: pmc7089128
pmid: 28447193  [indexed medline]

